Patterns and correlates of patient‐reported helpfulness of treatment for common mental and substance use disorders in the <scp>WHO</scp> World Mental Health Surveys

Kessler, Ronald C.; Kazdin, Alan E.; Aguilar‐Gaxiola, Sergio; Al‐Hamzawi, Ali; Alonso, Jordi; Altwaijri, Yasmin; Andrade, Laura Helena; Benjet, Corina; Bharat, Chrianna; Borges, Guilherme; Bruffærts, Ronny; Bunting, Brendan; Almeida, José Miguel Caldas de; Cardoso, Graça; Chiu, Wai Tat; Cía, Alfredo; Ciutan, Marius; Degenhardt, Louisa; Girolamo, Giovanni de; Jonge, Peter de; Vries, Ymkje Anna de; Florescu, Silvia; Gureje, Oye; Haro, Josep María; Harris, Meredith; Hu, Chiyi; Karam, Aimée; Karam, Elie G.; Karam, Georges; Kawakami, Norito; Kiejna, Andrzej; Kovess–Masféty, Viviane; Lee, Paul; Makanjuola, Victor; McGrath, John J.; Medina‐Mora, María Elena; Moskalewicz, Jacek; Navarro‐Mateu, Fernando; Nierenberg, Andrew A.; Nishi, Daisuke; Ojagbemi, Akin; Oladeji, Bibilola D.; O’Neill, Siobhan; Posada‐Villa, José; Puac‐Polanco, Victor; Rapsey, Charlene; Ruscio, Ayelet Meron; Sampson, Nancy A.; Scott, Kate M.; Slade, Tim; Stagnaro, Juan Carlos; Stein, Dan J.; Tachimori, Hisateru; Have, Margreet ten; Torres, Yolanda; Viana, María Carmen; Vigo, Daniel; Williams, David R.; Wojtyniak, Bogdan; Xavier, Miguel; Zarkov, Zahari; Ziobrowski, Hannah N.

doi:10.1002/wps.20971

Cited by 24 publications

(15 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, results of a recent analysis in the WHO World Mental Health Surveys underscores that persistence with next-step treat ments is uncommon in persons with MDD 82 . Also, in those who do switch to nextstep treat ments, a considerable treatment delay (i.e., 6-9 months) elapses before switching occurs 82,83 .…”

Section: Definitions Of Treatment-resistant Depressionmentioning

confidence: 99%

“…The use of measures such as the World Health Organi zation-Five Well-Being Index (WHO-5) may be suggested for this purpose 170 . More in general, therapeutic endpoints that inte grate patient-reported outcomes along with symptomatic measures may provide a more precise characterization of response to treatment 82 .…”

Section: Assessing Outcome Of Previous Antidepressant Trialsmentioning

confidence: 99%

See 1 more Smart Citation

Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions

McIntyre,

Alsuwaidan,

Baune

et al. 2023

World Psychiatry

Self Cite

185

View full text Add to dashboard Cite

Treatment‐resistant depression (TRD) is common and associated with multiple serious public health implications. A consensus definition of TRD with demonstrated predictive utility in terms of clinical decision‐making and health outcomes does not currently exist. Instead, a plethora of definitions have been proposed, which vary significantly in their conceptual framework. The absence of a consensus definition hampers precise estimates of the prevalence of TRD, and also belies efforts to identify risk factors, prevention opportunities, and effective interventions. In addition, it results in heterogeneity in clinical practice decision‐making, adversely affecting quality of care. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have adopted the most used definition of TRD (i.e., inadequate response to a minimum of two antidepressants despite adequacy of the treatment trial and adherence to treatment). It is currently estimated that at least 30% of persons with depression meet this definition. A significant percentage of persons with TRD are actually pseudo‐resistant (e.g., due to inadequacy of treatment trials or non‐adherence to treatment). Although multiple sociodemographic, clinical, treatment and contextual factors are known to negatively moderate response in persons with depression, very few factors are regarded as predictive of non‐response across multiple modalities of treatment. Intravenous ketamine and intranasal esketamine (co‐administered with an antidepressant) are established as efficacious in the management of TRD. Some second‐generation antipsychotics (e.g., aripiprazole, brexpiprazole, cariprazine, quetiapine XR) are proven effective as adjunctive treatments to antidepressants in partial responders, but only the olanzapine‐fluoxetine combination has been studied in FDA‐defined TRD. Repetitive transcranial magnetic stimulation (TMS) is established as effective and FDA‐approved for individuals with TRD, with accelerated theta‐burst TMS also recently showing efficacy. Electroconvulsive therapy is regarded as an effective acute and maintenance intervention in TRD, with preliminary evidence suggesting non‐inferiority to acute intravenous ketamine. Evidence for extending antidepressant trial, medication switching and combining antidepressants is mixed. Manual‐based psychotherapies are not established as efficacious on their own in TRD, but offer significant symptomatic relief when added to conventional antidepressants. Digital therapeutics are under study and represent a potential future clinical vista in this population.

show abstract

Section: Definitions Of Treatment-resistant Depressionmentioning

confidence: 99%

Section: Assessing Outcome Of Previous Antidepressant Trialsmentioning

confidence: 99%

Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions

McIntyre,

Alsuwaidan,

Baune

et al. 2023

World Psychiatry

Self Cite

185

View full text Add to dashboard Cite

show abstract

“…8 Estimates of the incidence and lifetime prevalence of bipolar disorder show moderate variations according to the method of diagnosis (performed by lay interviewers in a research context v clinically trained interviews) and the racial, ethnic, and demographic context. 9 Higher income, westernized countries have slightly higher rates of bipolar disorder, 10 which might reflect a combination of westernized centricity in the specific idioms used to understand and elicit symptoms, as well as a greater knowledge, acceptance, and conceptualization of emotional symptoms as psychiatric disorders.…”

Section: Epidemiologymentioning

confidence: 99%

Diagnosis and management of bipolar disorders

Goes

2023

BMJ

View full text Add to dashboard Cite

Bipolar disorders (BDs) are recurrent and sometimes chronic disorders of mood that affect around 2% of the world’s population and encompass a spectrum between severe elevated and excitable mood states (mania) to the dysphoria, low energy, and despondency of depressive episodes. The illness commonly starts in young adults and is a leading cause of disability and premature mortality. The clinical manifestations of bipolar disorder can be markedly varied between and within individuals across their lifespan. Early diagnosis is challenging and misdiagnoses are frequent, potentially resulting in missed early intervention and increasing the risk of iatrogenic harm. Over 15 approved treatments exist for the various phases of bipolar disorder, but outcomes are often suboptimal owing to insufficient efficacy, side effects, or lack of availability. Lithium, the first approved treatment for bipolar disorder, continues to be the most effective drug overall, although full remission is only seen in a subset of patients. Newer atypical antipsychotics are increasingly being found to be effective in the treatment of bipolar depression; however, their long term tolerability and safety are uncertain. For many with bipolar disorder, combination therapy and adjunctive psychotherapy might be necessary to treat symptoms across different phases of illness. Several classes of medications exist for treating bipolar disorder but predicting which medication is likely to be most effective or tolerable is not yet possible. As pathophysiological insights into the causes of bipolar disorders are revealed, a new era of targeted treatments aimed at causal mechanisms, be they pharmacological or psychosocial, will hopefully be developed. For the time being, however, clinical judgment, shared decision making, and empirical follow-up remain essential elements of clinical care. This review provides an overview of the clinical features, diagnostic subtypes, and major treatment modalities available to treat people with bipolar disorder, highlighting recent advances and ongoing therapeutic challenges.

show abstract

“…This tool is also utilized in various WHO-WMH surveys such as the National Survey of Mental Health and Wellbeing 17 from Australia, the US National Comorbidity Survey Replication (NCS-R), 18 and the World Mental Health Japan Survey, 19 allowing for national comparison studies. Moreover, numerous studies [20][21][22][23] have been conducted based on these data.…”

Section: Diagnostic Assessment Toolmentioning

confidence: 99%

Prevalence of Mental Disorders and Associated Factors in Korean Adults: National Mental Health Survey of Korea 2021

Rim¹,

Hahm

Seong

et al. 2023

Psychiatry Investig

View full text Add to dashboard Cite

Objective Mental health is a global concern and needs to be studied more closely. We aimed to estimate the prevalence of mental disorders and their associated factors among the general population in Korea.Methods The National Mental Health Survey of Korea 2021 was conducted between June 19 and August 31, 2021 and included 13,530 households; 5,511 participants completed the interview (response rate: 40.7%). The lifetime and 12-month diagnosis rates of mental disorders were made using the Korean version of the Composite International Diagnostic Interview 2.1. Factors associated with alcohol use disorder (AUD), nicotine use disorder, depressive disorder, and anxiety disorder were analyzed, and mental health service utilization rates were estimated.Results The lifetime prevalence of mental disorders was 27.8%. The 12-month prevalence rates of alcohol use, nicotine use, depressive, and anxiety disorders were 2.6%, 2.7%, 1.7%, and 3.1%, respectively. The risk factors associated with 12-month diagnosis rates were as follows: AUD: sex and age; nicotine use disorder: sex; depressive disorder: marital status and job status; anxiety disorder: sex, marital status, and job status. The 12-month treatment and service utilization rates for 12-month AUD, nicotine use disorder, depressive disorder, and anxiety disorder were 2.6%, 1.1%, 28.2%, and 9.1%, respectively.Conclusion Approximately 25% of adults in the general population were diagnosed with mental disorders during their lifetime. The treatment rates were substantially low. Future studies on this topic and efforts to increase the mental health treatment rate at a national level are needed.

show abstract

Patterns and correlates of patient‐reported helpfulness of treatment for common mental and substance use disorders in the WHO World Mental Health Surveys

Cited by 24 publications

References 40 publications

Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions

Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions

Diagnosis and management of bipolar disorders

Prevalence of Mental Disorders and Associated Factors in Korean Adults: National Mental Health Survey of Korea 2021

Contact Info

Product

Resources

About